...
首页> 外文期刊>Apoptosis: An international journal on programmed cell death >Synergistic protective effect of paeoniflorin and beta-ecdysterone against rotenone-induced neurotoxicity in PC12 cells
【24h】

Synergistic protective effect of paeoniflorin and beta-ecdysterone against rotenone-induced neurotoxicity in PC12 cells

机译:eon药苷和β-蜕皮甾酮对鱼藤酮诱导的PC12细胞神经毒性的协同保护作用

获取原文
获取原文并翻译 | 示例
           

摘要

There are several factors, like oxidative stress and neurons loss, involving neurodegenerative diseases such as Parkinson's disease (PD). The combination of antioxidant and anti-apoptotic agent is becoming a promising approach to fight against PD. This study evaluates the hypothesis that paeoniflorin (PF) and beta-ecdysterone (beta-Ecd) synergize to protect PC12 cells against toxicity induced by PD-related neurotoxin rotenone. The combination of PF and beta-Ecd, hereafter referred to as the PF/beta-Ecd, at suboptimal concentrations increased the viability of rotenone-exposed PC12 cells in a synergistic manner. PF and beta-Ecd cooperate to attenuate the rotenone-induced apoptosis by decrease in Bax expression, caspase-9 activity, and caspase-3 activity. PF or PF/beta-Ecd, but not beta-Ecd, inhibited rotenone-triggered protein kinase C-delta kinase C-delta (PKC delta) upregulation and nuclear factor kappa B (NF-kappa B) activation. beta-Ecd or PF/beta-Ecd, but not PF, enhanced serine/threonine protein kinase (Akt) activation, promoted nuclear factor E2-related factor 2 (Nrf2) nuclear accumulation, suppressed reactive oxygen species (ROS) production. Neuroprotection of PF/beta-Ecd could be completely blocked by PKC delta inhibitor rottlerin plus Akt specific inhibitor LY294002. Dual blockade of the PKC delta/NF-kappa B pathway by PF and activation of Akt/Nrf2 pathway by beta-Ecd results in a synergistic neuroprotective effect against rotenone-induced neurotoxicity in vitro. These findings provide the rationale for determining the in vivo activity of combined therapy with PF and beta-Ecd against PD.
机译:存在多种因素,例如氧化应激和神经元丢失,涉及神经退行性疾病,例如帕金森氏病(PD)。抗氧化剂和抗凋亡剂的组合正在成为对抗PD的有前途的方法。这项研究评估了pa药苷(PF)和β-蜕皮甾酮(β-Ecd)协同保护PC12细胞免受PD相关神经毒素鱼藤酮诱导的毒性这一假说。 PF和β-Ecd的组合(以下称为PF /β-Ecd)在次适浓度下以协同方式提高了鱼藤酮暴露的PC12细胞的活力。 PF和β-Ecd通过降低Bax表达,caspase-9活性和caspase-3活性来减弱鱼藤酮诱导的细胞凋亡。 PF或PF /β-Ecd,但不抑制β-Ecd,抑制鱼藤酮触发的蛋白激酶C-δ激酶C-δ(PKCδ)上调和核因子κB(NF-κB)激活。 β-Ecd或PF /β-Ecd,但不增强PF,增强了丝氨酸/苏氨酸蛋白激酶(Akt)的激活,促进了核因子E2相关因子2(Nrf2)的核积累,抑制了活性氧(ROS)的产生。 PKCδ抑制剂rottlerin加Akt特异性抑制剂LY294002可以完全阻断PF /β-Ecd的神经保护作用。 PF对PKC delta /NF-κB通路的双重阻滞和β-Ecd对Akt / Nrf2通路的激活导致对鱼藤酮诱导的体外神经毒性具有协同的神经保护作用。这些发现为确定联合PF和β-Ecd治疗PD的体内活性提供了理论依据。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号